Loading data…
Explore company-wide revenue, income and balance-sheet facts directly from SEC filings.
$122.64M net income for the year ended December 31, 2025. These are reported results, not a forecast or a stock recommendation.
Latest-filed standard financial facts · USD
Bars show magnitude; labels retain the sign. Each observation covers a reported annual period of 330–400 days; transition years can differ.
Reported periods can differ from calendar years. Later filings may restate earlier figures. These are company-wide facts; product and geographic revenue segments are not included.
| Reported period | Reported value | Filed | Source |
|---|---|---|---|
| January 1, 2025 – December 31, 2025 | $885,627,000 | April 30, 2026 | 20-F ↗ |
| January 1, 2024 – December 31, 2024 | $803,552,000 | April 30, 2026 | 20-F ↗ |
| January 1, 2023 – December 31, 2023 | $639,142,000 | April 30, 2026 | 20-F ↗ |
| January 1, 2022 – December 31, 2022 | $945,921,000 | April 30, 2025 | 20-F ↗ |
| January 1, 2021 – December 31, 2021 | $922,100,000 | April 30, 2024 | 20-F ↗ |
| January 1, 2020 – December 31, 2020 | $539,521,000 | April 28, 2023 | 20-F ↗ |
| January 1, 2019 – December 31, 2019 | $457,253,000 | April 25, 2022 | 20-F ↗ |
| January 1, 2018 – December 31, 2018 | $530,348,000 | May 12, 2021 | 20-F ↗ |
One standard US-GAAP or IFRS concept is selected per metric, using USD only. Annual durations must be 330–400 days. Quarterly durations must be 70–110 days; year-to-date totals are excluded, and fourth quarters are never inferred by subtraction. Cash-flow quarters can therefore be sparse. Conflicting values filed on the same day are excluded. Latest-filed values are used, so these observations must not be treated as facts known in an earlier backtest.
Concept: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax · Retrieved October 12, 2026
Response SHA-256: 69bd62ea71ae1dd0bdf18a9cc7035f9c7b834e0c1f7714e8fcb21e01acc47d39
Company-wide USD figures from SEC filings. Each card keeps its own reporting date; later filings can revise earlier results.